Tietoja työnantajasta
We are the MOGLYNET-PhD programme in drug discovery and development.
The Horizon 2020 MSCA joint doctoral project MoGglyNet (“Modulation of glycolytic flux as a new approach for treatment of atherosclerosis and plaque stabilization: a multidisciplinary study”) is run by a Consortium of Universities in cooperation with Industries and Associations operating in the Pharma sector with the aim to offer an innovative PhD level training in Drug Discovery and Development to 12 Early Stage Researchers.
The MOGLYNET PhD programme aims to define a new joint PhD educational model in Drug Discovery and Development and to promote institutional cooperation and mobility.
An active contribution of Industry in training activities is an important feature of the programme. The research methodologies and approaches proposed by the MOGLYNET consortium are strongly multidisciplinary and will involve a number of different state-of-the-art technologies and methodologies: Computational chemistry, Chemical synthesis; Bioanalytics and biophysics; In vitro biological evaluation; In vivo studies; Imaging; Metabolomics; Proteomics; Oxidative stress.